OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

OS Therapies advances OST-HER2 toward global regulatory filings, targeting near-term approvals.

What the company is saying

OS Therapies announces that the World Health Organization has approved 'Herlystic' as the proprietary name and 'daznelimgene lisbac' as the nonproprietary name for OST-HER2, clearing the final administrative hurdle for global regulatory submissions. The company frames this as a pivotal step, emphasizing imminent regulatory filings in the U.K. with the MHRA as lead agency under Project Orbis, and subsequent submissions to the FDA, EMA, and TGA. CEO Paul Romness states that filings will proceed in the coming weeks based on 2.5-year and interim 3-year overall survival data, with full 3-year data enabling broader submissions. The release highlights OST-HER2’s multiple regulatory designations—Orphan Drug, Fast Track, Rare Pediatric Disease, and Advanced Therapy Medicinal Product—across the FDA, EMA, and MHRA. The company stresses its eligibility for a Priority Review Voucher upon potential U.S. approval, referencing a recent $220 million PRV sale as a benchmark. The tone is confident and forward-leaning, focusing on regulatory momentum, clinical milestones, and the potential for near-term value creation.

What the data suggests

The announcement confirms WHO approval of both proprietary and nonproprietary names for OST-HER2, a necessary precursor for regulatory filings. OS Therapies is preparing to submit a Conditional Marketing Authorization Application to the MHRA in Q4 2026, with filings to the FDA, EMA, and TGA contingent on final 3-year overall survival data. The company references 2.5-year and interim 3-year OS data reviewed in a recent Scientific Advice Meeting but does not disclose specific survival rates or patient numbers. OST-HER2 has demonstrated clinically significant benefit in a Phase 2b trial for 12-month event free survival and overall survival in pulmonary metastatic osteosarcoma, but no detailed efficacy data is provided. The company has initiated a BLA submission with the FDA as of January 2026 and expects to supplement its application with additional historical control data from the U.K.'s Clinical Practice Research Datalink. Regulatory designations from FDA, EMA, and MHRA are confirmed, which should expedite review timelines. A recent Priority Review Voucher sale in August 2026 for $220 million is cited as a potential value benchmark if OS Therapies receives a PRV, but there is no guarantee of similar proceeds. No revenue, cash, or operational financials are disclosed. The data supports the narrative of regulatory progress but leaves clinical and commercial outcomes unquantified.

Analysis

The announcement is upbeat, highlighting regulatory progress (WHO name approvals, designations from FDA/EMA/MHRA) and the intention to initiate major regulatory submissions for OST-HER2. Several claims are realised (e.g., name/designation approvals, Phase 2b clinical benefit), but the majority of key value-driving statements are forward-looking: regulatory filings are planned but not yet completed, and pivotal 3-year OS data is still pending. The company references a recent $220M PRV sale as a potential future benefit, but this is contingent on regulatory approval and not guaranteed. No financials (revenue, profit, cash) are disclosed, and there is no evidence of immediate commercialisation or earnings impact. The tone is promotional, with language such as 'positioned to initiate' and 'intends to begin' inflating the sense of progress relative to actual realised milestones. However, the update is typical for a late-stage biotech and does not cross into red-flag territory.

Risk flags

• ●Regulatory approval risk is high, as OST-HER2’s value depends on successful Conditional Marketing Authorization and BLA approvals, which require robust 3-year OS data not yet disclosed. Any delay or negative outcome in these submissions would materially impact the company’s prospects.
• ●Clinical data transparency is limited; while the company claims clinically significant benefit in Phase 2b trials, no numerical survival rates or patient-level data are provided. This lack of detail makes it difficult for investors to independently assess efficacy or regulatory likelihood.
• ●Commercialization risk remains, as the company’s eligibility for a Priority Review Voucher and potential $220 million monetization is contingent on BLA approval and subsequent PRV sale, neither of which is assured. There is explicit acknowledgment that future PRV sales may not achieve comparable values.
• ●Financial opacity persists, with no disclosure of current cash, burn rate, or funding runway. The absence of operational financials or commercial agreements raises questions about the company’s ability to sustain operations through the regulatory process.
• ●Execution risk is present in the company’s multi-jurisdictional regulatory strategy, which involves concurrent submissions to the MHRA, FDA, EMA, and TGA. Coordination challenges and differing regulatory requirements could introduce delays or require additional data.

Bottom line

OS Therapies has cleared a key administrative step for OST-HER2 by securing WHO approval for its proprietary and nonproprietary names, enabling imminent regulatory filings in the U.K. and, pending final 3-year survival data, in the U.S., Europe, and Australia. The company’s lead asset has received multiple expedited review designations, positioning it for potentially faster approvals. A recent $220 million Priority Review Voucher sale is cited as a potential upside if the company achieves BLA approval, but this outcome is not guaranteed. The announcement is credible on regulatory progress but lacks detailed clinical efficacy data and provides no insight into financial health or commercial readiness. Investors should focus on the forthcoming regulatory submissions, the release of final 3-year OS data, and any updates on cash position or partnership activity. The most important takeaway is that regulatory and clinical milestones are approaching, but material value realization depends on successful approvals and transparent data.

Announcement summary

(NYSE American: OSTX) OS Therapies, Inc. announced that the World Health Organization (WHO) has approved 'Herlystic'™ as the proprietary brand name for OST-HER2, and previously approved 'daznelimgene lisbac' as the nonproprietary name for the ingredients in OST-HER2. With both names now approved, OS Therapies is positioned to initiate regulatory submissions for early market access for OST-HER2 worldwide. The company intends to begin international regulatory submissions in the U.K. at the invitation of the Medicines and Healthcare products Regulatory Agency (MHRA), followed by submissions to the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), and the Australian Therapeutic Goods Administration (TGA). MHRA will act as the lead international regulatory agency under Project Orbis, an FDA Oncology Center of Excellence initiative for concurrent submission and review of oncology products among international partners. Since 2021, 29 MHRA-led oncology products have been approved by the FDA under Project Orbis. Paul Romness, MPH, Chairman & CEO of OS Therapies, stated that the company is moving ahead with early market access regulatory filings, with MHRA's submission slated in the coming weeks based on 2.5-year and interim 3-year Overall Survival (OS) data, and subsequent submissions to FDA, EMA, and TGA once final 3-year OS data is available. MHRA, EMA, and TGA have agreed to use non-concurrent historical control to evaluate efficacy for OST-HER2's pending Conditional Marketing Authorization Application (CMAA) submissions, while the FDA uses surrogate clinical endpoints such as biomarkers for Biologics License Applications (BLAs) under the Accelerated Approval Program. OS Therapies is awaiting completion of 3-year OS data for a pending meeting with the Center for Drug Research Evaluation (CDER) to review the correlation between pharmacodynamic response biomarkers and overall survival as part of the Biomarker Qualification Program. The previously announced Type B Pre-BLA Meeting will occur once the full data package is complete, while BLA submission, initiated in January 2026, continues. The company expects to have sufficient additional concurrent external historical control comparator data via the Clinical Practice Research Datalink (CPRD) to support its BLA filing. OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD), and Rare Pediatric Disease Designation (RPDD) from the FDA; ODD, FTD, and Advanced Therapy Medicinal Products (ATMP) from the EMA; and ODD and ATMP from MHRA, which also recruited the company into Project Orbis. Under the RPDD program, if granted a BLA in the United States, OS Therapies will become eligible to receive a Priority Review Voucher (PRV) that it intends to sell. A recent PRV sale in August 2026 occurred for $220 million, though there is no assurance the company would realize a comparable value in any future PRV sale. OS Therapies has completed resubmission of a Regenerative Medicine Advanced Therapy (RMAT) request and its Commissioner's National Priority Review Voucher (CNPV) letter of intent has been accepted by the FDA. The company is seeking a Conditional Marketing Authorization Application from MHRA in the U.K. under Project Orbis for OST-HER2 in metastatic osteosarcoma in the fourth quarter of 2026, and immediately thereafter is seeking to obtain a BLA under the Accelerated Approval Program in the U.S., followed by CMAAs in Europe and Australia. OST-HER2 is the company's lead asset, an immunotherapy leveraging Listeria bacteria to target the HER2 protein, and has demonstrated clinically significant benefit in a Phase 2b clinical trial for the 12-month event free survival (EFS) primary endpoint and overall survival (OS) secondary endpoint in pulmonary metastatic osteosarcoma. OST-HER2 has completed a Phase 1 clinical study in breast cancer patients and shown preclinical efficacy in various breast cancer models. OST-HER2 was previously conditionally approved by the U.S. Department of Agriculture for treating canines with osteosarcoma. The company has completed dosing in a Phase 1 study of OST-504 for castration-resistant prostate cancer. OS Therapies is also advancing next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), featuring proprietary silicon Si-Linker and Conditionally Active Payload (CAP) technology.

Disagree with this article?